{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:03:32Z","timestamp":1791425012351,"version":"4.3.3"},"reference-count":45,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.coph.2011.07.008","type":"journal-article","created":{"date-parts":[[2011,8,21]],"date-time":"2011-08-21T15:00:39Z","timestamp":1313938839000},"page":"433-438","source":"Crossref","is-referenced-by-count":81,"title":["Resistance drives antibacterial drug development"],"prefix":"10.1016","volume":"11","author":[{"given":"Ursula","family":"Theuretzbacher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2011.07.008_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2010.05872.x","article-title":"The coming of age of antibiotics: discovery and therapeutic value","volume":"1213","author":"Bush","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.coph.2011.07.008_bib0010","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2011.279","article-title":"Preserving the lifesaving power of antimicrobial agents","author":"Hughes","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2011.07.008_bib0015","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ijantimicag.2011.01.012","article-title":"What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline","volume":"37","author":"Livermore","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.coph.2011.07.008_bib0020","doi-asserted-by":"crossref","first-page":"i29","DOI":"10.1093\/jac\/dkp255","article-title":"Has the era of untreatable infections arrived?","volume":"64","author":"Livermore","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coph.2011.07.008_bib0025_1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1128\/CMR.00030-10","article-title":"Challenges of antibacterial discovery","volume":"24","author":"Silver","year":"2011","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.coph.2011.07.008_bib0030","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2125.2010.03854.x","article-title":"Drug discovery: lessons from evolution","volume":"71","author":"Warren","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.coph.2011.07.008_bib0035_1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ijantimicag.2010.08.018","article-title":"Discovering new antimicrobial agents","volume":"37","author":"Moellering","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.coph.2011.07.008_bib0040","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002273","article-title":"How to revive breakthrough innovation in the pharmaceutical industry","volume":"3","author":"Munos","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2011.07.008_bib0045","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijantimicag.2009.02.005","article-title":"Future antibiotics scenarios: is the tide starting to turn?","volume":"34","author":"Theuretzbacher","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.coph.2011.07.008_bib0050","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nrmicro2200","article-title":"Waves of resistance: Staphylococcus aureus in the antibiotic era","volume":"7","author":"Chambers","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.coph.2011.07.008_bib0055","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/jac\/dkq538","article-title":"A 12 year (1998\u20132009) antibiotic resistance surveillance of Klebsiella pneumoniae collected from intensive care and urology patients in 14 Dutch hospitals","volume":"66","author":"van der Donk","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coph.2011.07.008_bib0060","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1476-5381.2011.01250.x","article-title":"Novel classes of antibiotics or more of the same?","volume":"163","author":"Coates","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.coph.2011.07.008_bib0065_1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.drup.2011.01.007","article-title":"The global need for effective antibiotics\u2014a summary of plenary presentations","volume":"14","author":"Alvan","year":"2011","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.coph.2011.07.008_bib0070","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/AAC.01009-09","article-title":"An updated functional classification of beta-lactamases","volume":"54","author":"Bush","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2011.07.008_bib0075","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1473-3099(11)70056-1","article-title":"Metallo-beta-lactamases: a last frontier for beta-lactams?","volume":"11","author":"Cornaglia","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coph.2011.07.008_bib0080_1","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.mib.2010.09.006","article-title":"Alarming beta-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae","volume":"13","author":"Bush","year":"2010","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.coph.2011.07.008_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2011.02.010","article-title":"First outbreak of VIM-2 metallo-beta-lactamase-producing Pseudomonas aeruginosa in The Netherlands: microbiology, epidemiology and clinical outcomes","author":"Van der Bij","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.coph.2011.07.008_bib0090","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.mib.2010.09.008","article-title":"The future of the [beta]-lactams","volume":"13","author":"Llarrull","year":"2010","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.coph.2011.07.008_bib0095","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1128\/AAC.01645-10","article-title":"Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish Multicenter Study","volume":"55","author":"Cabot","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2011.07.008_bib0100_1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1586\/eri.09.108","article-title":"Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy","volume":"8","author":"Zavascki","year":"2010","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.coph.2011.07.008_bib0105","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1469-0691.2006.01403.x","article-title":"Can \u03b2-lactams be re-engineered to beat MRSA?","volume":"12","author":"Livermore","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.coph.2011.07.008_bib0110","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/cid\/cir147","article-title":"Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus","volume":"52","author":"Saravolatz","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2011.07.008_bib0115","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/jac\/dkm150","article-title":"In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes","volume":"60","author":"Mushtaq","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coph.2011.07.008_bib0120","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/cc8892","article-title":"Bench-to-bedside review: the role of beta-lactamases in antibiotic-resistant Gram-negative infections","volume":"14","author":"Bush","year":"2010","journal-title":"Crit Care"},{"key":"10.1016\/j.coph.2011.07.008_bib0125","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/jac\/dkq248","article-title":"Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae","volume":"65","author":"Livermore","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coph.2011.07.008_bib0130","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1128\/AAC.00756-10","article-title":"Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae","volume":"55","author":"Livermore","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2011.07.008_bib0135_1","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/CMR.00037-09","article-title":"Three decades of beta-lactamase inhibitors","volume":"23","author":"Drawz","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.coph.2011.07.008_bib0140","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1128\/AAC.01525-09","article-title":"In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant Gram-negative bacilli","volume":"54","author":"Page","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2011.07.008_bib0145","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/jac\/dkr013","article-title":"In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumannii","volume":"66","author":"Russo","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coph.2011.07.008_bib0150","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/jac\/dkp425","article-title":"Activity of the siderophore monobactam BAL30072 against multiresistant non-fermenters","volume":"65","author":"Mushtaq","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coph.2011.07.008_bib0155","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1128\/CMR.15.4.647-679.2002","article-title":"Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance","volume":"15","author":"Martinez","year":"2002","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.coph.2011.07.008_bib0160","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.mib.2010.09.004","article-title":"Combating evolution with intelligent design: the neoglycoside ACHN-490","volume":"13","author":"Armstrong","year":"2010","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.coph.2011.07.008_bib0165","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1128\/AAC.00572-10","article-title":"Synthesis and spectrum of the neoglycoside ACHN-490","volume":"54","author":"Aggen","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2011.07.008_bib0170","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/jac\/dkq459","article-title":"Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City","volume":"66","author":"Landman","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coph.2011.07.008_bib0175","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/jac\/dkq408","article-title":"Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates","volume":"66","author":"Livermore","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coph.2011.07.008_bib0180","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1128\/AAC.49.2.479-487.2005","article-title":"Aminoglycoside resistance in Pseudomonas aeruginosa","volume":"49","author":"Poole","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2011.07.008_bib0185","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1128\/AAC.01197-09","article-title":"Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates","volume":"54","author":"Lauderdale","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2011.07.008_bib0190","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1128\/AAC.01150-08","article-title":"In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types","volume":"53","author":"Bhagwat","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2011.07.008_bib0195","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/187152110790886745","article-title":"From vancomycin to oritavancin: the discovery and development of a novel lipoglycopeptide antibiotic","volume":"9","author":"Allen","year":"2010","journal-title":"Anti Infect Agents Med Chem"},{"key":"10.1016\/j.coph.2011.07.008_bib0200","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1128\/AAC.01193-07","article-title":"Rx-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance","volume":"52","author":"Skripkin","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2011.07.008_bib0205","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.ejmech.2011.01.014","article-title":"Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent","volume":"46","author":"Im","year":"2011","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.coph.2011.07.008_bib0210","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1128\/AAC.01383-07","article-title":"In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens","volume":"52","author":"Lawrence","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2011.07.008_bib0215","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1128\/AAC.00663-10","article-title":"Structure\u2013activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations","volume":"54","author":"Locke","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2011.07.008_bib0220","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1128\/AAC.00076-10","article-title":"Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections","volume":"55","author":"Prokocimer","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2011.07.008_bib0225","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1128\/AAC.00860-10","article-title":"Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesis","volume":"54","author":"Llano-Sotelo","year":"2010","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489211001305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489211001305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T16:27:38Z","timestamp":1543595258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489211001305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S1471489211001305"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2011.07.008","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}